China's Center for Drug Evaluation accepted Merck's application for respiratory syncytial virus or RSV drug Clesrovimab, according to Yicai Global's Thursday report.
The drug was designed to prevent RSV infections in newborns and infants, the report said.
The US Food and Drug Administration's review into the drug is expected to end by June 10. It was first submitted to the FDA in December 2024, the report said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。